Article

Machine learning-based prediction of response to PARP inhibition across cancer types

2019-09-27

Abstract excerpt

PARP inhibitors (PARPi) are FDA approved for the treatment of BRCA1/2 deficient breast and ovarian cancer, but a growing body of pre-clinical evidence suggests the drug class holds therapeutic potential in other cancer types, independent of BRCA1/2 status. Large-scale pharmacogenomic datasets offer the opportunity to develop predictors of response to PARPi’s in many cancer types, expanding their potential clinical...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1c8c1972-57e9-53a1-927d-a0e134c9c04e
DOI: 10.1101/19007757

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Machine learning-based prediction of response to PARP inhibition across cancer typesDOI 10.1101/19007757Read

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor ResistanceSemantic proximity Read

A novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study.Semantic proximity Read

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibSemantic proximity Read

Understanding tumour growth variability in patient-derived breast cancer xenograft models identifies early responders and biomarkers of resistance to PARP inhibitionSemantic proximity Read

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancerSemantic proximity Read

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineSemantic proximity Read

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell LinesSemantic proximity Read

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.Semantic proximity Read

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical LandscapeSemantic proximity Read

PARP Inhibitors in Ovarian CancerSemantic proximity Read

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancerSemantic proximity Read

Molecular mechanism of PARP inhibitor resistanceSemantic proximity Read